Drugs / Antithrombin concentrate
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT06145373 Background | Mar 2024 → May 2028 expected | hemophilia A | Sanofi | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Antithrombin concentrate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06145373 ↗ |
| Route | Intravenous | “Route of administration:Intravenous (IV) injection” NCT06145373 ↗ |